Filing Details

Accession Number:
0000899243-19-029699
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-19 20:54:26
Reporting Period:
2019-12-17
Accepted Time:
2019-12-19 20:54:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1259856 Douglas Fambrough C/O Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington MA 02421
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-17 56,716 $26.13 14,605 No 4 S Direct
Common Stock Disposition 2019-12-17 2,305 $26.94 12,300 No 4 S Direct
Common Stock Acquisiton 2019-12-18 80,000 $3.42 92,300 No 4 M Direct
Common Stock Disposition 2019-12-18 78,569 $25.85 13,731 No 4 S Direct
Common Stock Disposition 2019-12-18 1,431 $27.07 12,300 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2019-12-18 80,000 $0.00 80,000 $3.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
201,250 2023-09-24 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.79, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.82 to $27.08, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.60 to $26.5950, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.1950, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
  6. Vested 1/48 monthly on last day of each month with a vesting start date of 07/30/2013.